Table Info

Table 1.

COVID-19 vaccines and their excipients

Vaccine	Type of vaccine	Excipients
Pfizer-BioNtech BNT162b2 (Comirnaty)	mRNA	PEG 2000, DSPC
AstraZeneca AZD1222 (Vaxzevria)	Non-replicating chimpanzee Ad	PS80, EDTA
Moderna mRNA-1273	mRNA	PEG 2000, DSPC
Johnson & Johnson COVID-19 vaccine (JNJ-78436725)	Recombinant, replication-incompetent, Ad-based vaccine	PS80
Gam-COVID-Vac (Sputnik V)	Recombinant, replication-incompetent, Ad-based vaccine	PS80, EDTA
Novavax NVX-CoV2373 (Nuvaxovid)	Protein based vaccine	PS80
SinoVac Biotech COVID-19 vaccine (CoronaVac)	Inactivated vaccine	-

-: No excipients

Note. Adapted with permission from “Allergies and COVID-19 vaccines: an ENDA/EAACI position paper,” by Barbaud A, Garvey LH, Arcolaci A, Brockow K, Mori F, Mayorga C, et al. Allergy. 2022;77:2292–312 (https://onlinelibrary.wiley.com/doi/10.1111/all.15241). © 2022 EAACI and John Wiley and Sons A/S.

Declarations

Author contributions

FV and DGS: Investigation, Writing—original draft, Writing—review & editing. GC: Investigation, Writing—original draft, Conceptualization, Writing—review & editing. DP, FP, IZ, GL, MAL, GP, CMC, and VN: Investigation, Writing—original draft. DDB: Investigation, Writing—original draft, Validation, Supervision. EN: Conceptualization, Investigation, Writing—original draft, Validation, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Parasher A. COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021;97:312–20. [DOI] [PubMed] [PMC]

Muhar BK, Nehira J, Malhotra A, Kotchoni SO. The race for COVID-19 vaccines: the various types and their strengths and weaknesses. J Pharm Pract. 2023;36:953–66. [DOI] [PubMed] [PMC]

Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28:202–21. [DOI] [PubMed] [PMC]

Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21:626–36. [DOI] [PubMed] [PMC]

Barbaud A, Garvey LH, Arcolaci A, Brockow K, Mori F, Mayorga C, et al. Allergies and COVID-19 vaccines: an ENDA/EAACI position paper. Allergy. 2022;77:2292–312. [DOI] [PubMed]

Rutkowski K, Mirakian R, Till S, Rutkowski R, Wagner A. Adverse reactions to COVID-19 vaccines: a practical approach. Clin Exp Allergy. 2021;51:770–7. [DOI] [PubMed] [PMC]

Radice A, Fassio F, Meucci E, Iorno MCL, Macchia D. Potential culprits for immediate hypersensitivity reactions to BNT162b2 mRNA COVID-19 vaccine: not just PEG. Eur Ann Allergy Clin Immunol. 2021;53:240–2. [DOI] [PubMed]

AlMuhizi F, Ton-Leclerc S, Fein M, Tsoukas C, Garvey LH, Lee D, et al. Successful desensitization to mRNA COVID-19 vaccine in a case series of patients with a history of anaphylaxis to the first vaccine dose. Front Allergy. 2022;3:825164. [DOI] [PubMed] [PMC]

Wan EYF, Wang Y, Chui CSL, Mok AHY, Xu W, Yan VKC, et al. Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series. Lancet Healthy Longev. 2022;3:e491–500. [DOI] [PubMed] [PMC]

10.

Borgsteede SD, Geersing TH, Tempels-Pavlica Ž. Other excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines. Allergy. 2021;76:1941–2. [DOI] [PubMed] [PMC]

11.

Fruijtier-Pölloth C. Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. Toxicology. 2005;214:1–38. [DOI] [PubMed]

12.

Henning T. Polyethylene glycols (PEGs) and the pharmaceutical industry. SÖFW-J. 2001;127:28–32.

13.

Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46:907–22. [DOI] [PubMed]

14.

Chadwick VS, Phillips SF, Hofmann AF. Measurements of intestinal permeability using low molecular weight polyethylene glycols (PEG 400). I. Chemical analysis and biological properties of PEG 400. Gastroenterology. 1977;73:241–6. [PubMed]

15.

Wang T, Guo Y, He Y, Ren T, Yin L, Fawcett JP, et al. Impact of molecular weight on the mechanism of cellular uptake of polyethylene glycols (PEGs) with particular reference to P-glycoprotein. Acta Pharm Sin B. 2020;10:2002–9. [DOI] [PubMed] [PMC]

16.

Spoerl D, Scherer K, Bircher AJ. Contact urticaria with systemic symptoms due to hexylene glycol in a topical corticosteroid: case report and review of hypersensitivity to glycols. Dermatology. 2010;220:238–42. [DOI] [PubMed]

17.

Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010;49:6288–308. [DOI] [PubMed]

18.

Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al.; mRNA-1273 Study Group. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384:80–2. [DOI] [PubMed] [PMC]

19.

Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: Is polyethylene glycol (PEG) the culprit? Br J Anaesth. 2021;126:e106–8. [DOI] [PubMed] [PMC]

20.

Cabanillas B, Akdis CA, Novak N. Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol? Allergy. 2021;76:1617–8. [DOI] [PubMed]

21.

Calogiuri G, Foti C, Nettis E, Di Leo E, Macchia L, Vacca A. Polyethylene glycols and polysorbates: two still neglected ingredients causing true IgE-mediated reactions. J Allergy Clin Immunol Pract. 2019;7:2509–10. [DOI] [PubMed]

22.

Coors EA, Seybold H, Merk HF, Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005;95:593–9. [DOI] [PubMed]

23.

Knoch H, Ulbrich MH, Mittag JJ, Buske J, Garidel P, Heerklotz H. Complex micellization behavior of the polysorbates Tween 20 and Tween 80. Mol Pharm. 2021;18:3147–57. [DOI] [PubMed]

24.

Jones MT, Mahler HC, Yadav S, Bindra D, Corvari V, Fesinmeyer RM, et al. Considerations for the use of polysorbates in biopharmaceuticals. Pharm Res. 2018;35:148. [DOI] [PubMed]

25.

Ieven T, Van Weyenbergh T, Vandebotermet M, Devolder D, Breynaert C, Schrijvers R. Tolerability of polysorbate 80–containing COVID-19 vaccines in confirmed polyethylene glycol–allergic patients. J Allergy Clin Immunol Pract. 2021;9:4470–2.e1. [DOI] [PubMed] [PMC]

26.

Badiu I, Geuna M, Heffler E, Rolla G. Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80. BMJ Case Rep. 2012;2012:bcr0220125797. [DOI] [PubMed] [PMC]

27.

Pérez-Pérez L, García-Gavín J, Piñeiro B, Zulaica A. Biologic-induced urticaria due to polysorbate 80: usefulness of prick test. Br J Dermatol. 2011;164:1119–20. [DOI] [PubMed]

28.

Steele RH, Limaye S, Cleland B, Chow J, Suranyi MG. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology (Carlton). 2005;10:317–20. [DOI] [PubMed]

29.

Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc. 2007;28:313–9. [DOI] [PubMed]

30.

Hart JR. Ethylenediaminetetraacetic acid and related chelating agents. In: Ley C, Elvers B, Bellussi G, Bus J, Greim H, Hessel V, et al., editors. Ullmann’s encyclopedia of industrial chemistry. Wiley-VCH Verlag GmbH & Co. KGaA; 2011. [DOI]

31.

Lombardo M, Espósito BP, Lourenço FR, Kaneko TM. The application of pharmaceutical quality by design concepts to evaluate the antioxidant and antimicrobial properties of a preservative system including desferrioxamine. Daru. 2020;28:635–46. [DOI] [PubMed] [PMC]

32.

Cabanillas B, Novak N. Allergy to COVID-19 vaccines: a current update. Allergol Int. 2021;70:313–8. [DOI] [PubMed] [PMC]

33.

Lukawska J, Mandaliya D, Chan AWE, Foggitt A, Bidder T, Harvey J, et al. Anaphylaxis to trometamol excipient in gadolinium-based contrast agents for clinical imaging. J Allergy Clin Immunol Pract. 2019;7:1086–7. [DOI] [PubMed]

34.

Dreskin SC, Halsey NA, Kelso JM, Wood RA, Hummell DS, Edwards KM, et al. International consensus (ICON): allergic reactions to vaccines. World Allergy Organ J. 2016;9:32. [DOI] [PubMed] [PMC]

35.

Hung SI, Preclaro IAC, Chung WH, Wang CW. Immediate hypersensitivity reactions induced by COVID-19 vaccines: current trends, potential mechanisms and prevention strategies. Biomedicines. 2022;10:1260. [DOI] [PubMed] [PMC]

36.

Palacios Castaño MI, Venturini Díaz M, Lobera Labairu T, González Mahave I, Del Pozo Gil MD, Blasco Sarramián A. Anaphylaxis due to the excipient polysorbate 80. J Investig Allergol Clin Immunol. 2016;26:394–6. [DOI] [PubMed]

37.

Neun BW, Ilinskaya AN, Dobrovolskaia MA. Analysis of complement activation by nanoparticles. Methods Mol Biol. 2018;1682:149–60. [DOI] [PubMed]

38.

Inglut CT, Sorrin AJ, Kuruppu T, Vig S, Cicalo J, Ahmad H, et al. Immunological and toxicological considerations for the design of liposomes. Nanomaterials (Basel). 2020;10:190. [DOI] [PubMed] [PMC]

39.

Weiszhár Z, Czúcz J, Révész C, Rosivall L, Szebeni J, Rozsnyay Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci. 2012;45:492–8. [DOI] [PubMed]

40.

Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, van Oosterom A, et al. Coping with toxicities of docetaxel (Taxotere^TM). Ann Oncol. 1993;4:610–1. [DOI] [PubMed]

41.

Norris LB, Qureshi Z, Bookstaver B, Raisch DW, Sartor O, Chen H, et al. Polysorbate 80 hypersensitivity reactions: a renewed call to action. Community Oncol. 2010;7:425–8. [DOI]

42.

Linee di indirizzo per l’inquadramento e la gestione dei pazienti a rischio di reazioni allergiche ai vaccini per il COVID-19 [Internet]. Firenze: AAIITO; c2024 [cited 2023 Feb 1]. Available from: https://www.aaiito.it/news/linee-di-indirizzo-per-linquadramento-e-la-gestione-dei-pazienti-a-rischio-di-reazioni-allergiche-ai-vaccini-per-il-covid-19/

43.

Restivo V, Candore G, Barrale M, Caravello E, Graziano G, Onida R, et al. Allergy to polyethilenglicole of anti-SARS CoV2 vaccine recipient: a case report of young adult recipient and the management of future exposure to SARS-CoV2. Vaccines (Basel). 2021;9:412. [DOI] [PubMed] [PMC]

44.

Wagner N, Podda M. High volume of polysorbate-containing (Tween^® 80) solutions induces false-positive results in intradermal test. J Eur Acad Dermatol Venereol. 2018;32:1972–6. [DOI] [PubMed]

45.

Banerji A, Wickner PG, Saff R, Stone CA Jr, Robinson LB, Long AA, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2021;9:1423–37. [DOI] [PubMed] [PMC]

46.

Krantz MS, Bruusgaard-Mouritsen MA, Koo G, Phillips EJ, Stone CA Jr, Garvey LH. Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don’t give up on the second dose! Allergy. 2021;76:2916–20. [DOI] [PubMed] [PMC]

47.

Wolfson AR, Robinson LB, Li L, McMahon AE, Cogan AS, Fu X, et al. First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing. J Allergy Clin Immunol Pract. 2021;9:3308–20.e3. [DOI] [PubMed] [PMC]

48.

ALMuhizi F, Fein M, Gabrielli S, Gilbert L, Tsoukas C, Ben-Shoshan M, et al. Allergic reactions to the coronavirus disease 2019 vaccine (ARCOV) study: the McGill University Health Centre experience. Ann Allergy Asthma Immunol. 2022;129:182–8.e1. [DOI] [PubMed] [PMC]

49.

Otani IM, Tsao LR, Tang M. Coronavirus disease 2019 vaccine administration in patients with reported reactions to polyethylene glycol- and polysorbate-containing therapeutics. Ann Allergy Asthma Immunol. 2022;129:88–94.e1. [DOI] [PubMed] [PMC]

50.

Mortz CG, Kjaer HF, Rasmussen TH, Rasmussen HM, Garvey LH, Bindslev-Jensen C. Allergy to polyethylene glycol and polysorbates in a patient cohort: diagnostic work-up and decision points for vaccination during the COVID-19 pandemic. Clin Transl Allergy. 2022;12:e12111. [DOI] [PubMed] [PMC]

51.

Vidal Oribe I, Venturini Díaz M, Hernández Alfonso P, Del Pozo Gil MD, González Mahave I, Lobera Labairu T. Tolerance to SARS CoV-2 vaccines containing polyethylene glycol in patients allergic to polysorbate 80. J Investig Allergol Clin Immunol. 2022;32:403–5. [DOI] [PubMed]

52.

Bruusgaard-Mouritsen MA, Jensen BM, Poulsen LK, Duus Johansen J, Garvey LH. Optimizing investigation of suspected allergy to polyethylene glycols. J Allergy Clin Immunol. 2022;149:168–75.e4. [DOI] [PubMed]

53.

Klimek L, Novak N, Cabanillas B, Jutel M, Bousquet J, Akdis CA. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation. Allergy. 2021;76:3307–13. [DOI] [PubMed] [PMC]

54.

Csuth À, Nopp A, Storsaeter J, Nilsson L, Jenmalm MC. COVID-19 vaccines and anaphylaxis—evaluation with skin prick testing, basophil activation test and immunoglobulin E. Clin Exp Allergy. 2022;52:812–9. [DOI] [PubMed] [PMC]

55.

Mouri M, Imamura M, Suzuki S, Kawasaki T, Ishizaki Y, Sakurai K, et al. Serum polyethylene glycol-specific IgE and IgG in patients with hypersensitivity to COVID-19 mRNA vaccines. Allergol Int. 2022;71:512–9. [DOI] [PubMed] [PMC]

56.

Troelnikov A, Perkins G, Yuson C, Ahamdie A, Balouch S, Hurtado PR, et al. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy. J Allergy Clin Immunol. 2021;148:91–5. [DOI] [PubMed]

57.

McSweeney MD, Mohan M, Commins SP, Lai SK. Anaphylaxis to Pfizer/BioNTech mRNA COVID-19 vaccine in a patient with clinically confirmed PEG allergy. Front Allergy. 2021;2:715844. [DOI] [PubMed] [PMC]

58.

Labella M, Céspedes JA, Doña I, Shamji MH, Agache I, Mayorga C, et al. The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine. Allergy. 2022;77:2067–79. [DOI] [PubMed] [PMC]

59.

Eberlein B, Mathes S, Fischer J, Darsow U, Biedermann T, Brockow K. Do basophil activation tests help elucidate allergic reactions to the ingredients in COVID-19 vaccines? Allergy. 2022;77:2924–36. [DOI] [PubMed] [PMC]

60.

Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N Engl J Med. 2021;384:1273–7. [DOI] [PubMed] [PMC]

61.

Azenha Rama T, Moço Coutinho R, Mota D, Moreira A, Cernadas J. Hypersensitivity to the moderna COVID-19 vaccine caused by tromethamine: PEG is not always the culprit excipient. J Investig Allergol Clin Immunol. 2022;32:414–5. [DOI] [PubMed]

62.

Greenhawt M, Shaker M, Golden DBK, Abrams EM, Blumenthal KG, Wolfson AR, et al. Diagnostic accuracy of vaccine and vaccine excipient testing in the setting of allergic reactions to COVID-19 vaccines: a systematic review and meta-analysis. Allergy. 2023;78:71–83. [DOI] [PubMed] [PMC]

63.

Mi YN, Yan PP, Yu RH, Xiao X, Wang J, Cao L. Non-IgE-mediated hypersensitivity induced by multivitamins containing Tween-80. Clin Exp Pharmacol Physiol. 2019;46:664–75. [DOI] [PubMed]

64.

Cha B, Kwon KS, Lee HL, Kim CW. Successful mRNA COVID-19 vaccination and colonoscopy after oral desensitization in a patient with polyethylene glycol allergy. J Korean Med Sci. 2022;37:e251. [DOI] [PubMed] [PMC]

65.

Bent RK, Weinbrenner J, Faihs V, Steffens S, Nau T, Vitus M, et al. Increasing the COVID-19 immunization rate through allergy testing. J Eur Acad Dermatol Venereol. 2023;37:1228–35. [DOI] [PubMed]

66.

Sellaturay P, Nasser S, Ewan P. Polyethylene glycol–induced systemic allergic reactions (anaphylaxis). J Allergy Clin Immunol Pract. 2021;9:670–5. [DOI] [PubMed]